C D Binde1, I F Tvete2, J Gåsemyr3, B Natvig3, M Klemp1. 1. Department of Pharmacology, University of Oslo, Oslo, Norway. 2. Norwegian Computing Centre, Oslo, Norway. 3. Department of Mathematics, University of Oslo, Oslo, Norway.
Abstract
AIMS: To the best of our knowledge, there are no systematic reviews or meta-analyses that compare rasagiline, selegiline and safinamide. Therefore, we aimed to perform a drug class review comparing all available monoamine oxidase type B (MAO-B) inhibitors in a multiple treatment comparison. METHODS: We performed a systematic literature search to identify randomized controlled trials assessing the efficacy of MAO-B inhibitors in patients with Parkinson's disease. MAO-B inhibitors were evaluated either as monotherapy or in combination with levodopa or dopamine agonists. Endpoints of interest were change in the Unified Parkinson's Disease Rating Scale (UPDRS) score and serious adverse events. We estimated the relative effect of each MAO-B inhibitor versus the comparator drug by creating three networks of direct and indirect comparisons. For each of the networks, we considered a joint model. RESULTS: The systematic literature search and study selection process identified 27 publications eligible for our three network analyses. We found the relative effects of rasagiline, safinamide and selegiline treatment given alone and compared to placebo in a model without explanatory variables to be 1.560 (1.409, 1.734), 1.449 (0.873, 2.413) and 1.532 (1.337, 1.757) respectively. We also found all MAO-B inhibitors to be efficient when given together with levodopa. When ranking the MAO-B inhibitors given in combination with levodopa, selegiline was the most effective and rasagiline was the second best. CONCLUSIONS: All of the included MAO-B inhibitors were effective compared to placebo when given as monotherapy. Combination therapy with MAO-B inhibitors and levodopa showed that all three MAO-B inhibitors were effective compared to placebo, but selegiline was the most effective drug.
AIMS: To the best of our knowledge, there are no systematic reviews or meta-analyses that compare rasagiline, selegiline and safinamide. Therefore, we aimed to perform a drug class review comparing all available monoamine oxidase type B (MAO-B) inhibitors in a multiple treatment comparison. METHODS: We performed a systematic literature search to identify randomized controlled trials assessing the efficacy of MAO-B inhibitors in patients with Parkinson's disease. MAO-B inhibitors were evaluated either as monotherapy or in combination with levodopa or dopamine agonists. Endpoints of interest were change in the Unified Parkinson's Disease Rating Scale (UPDRS) score and serious adverse events. We estimated the relative effect of each MAO-B inhibitor versus the comparator drug by creating three networks of direct and indirect comparisons. For each of the networks, we considered a joint model. RESULTS: The systematic literature search and study selection process identified 27 publications eligible for our three network analyses. We found the relative effects of rasagiline, safinamide and selegiline treatment given alone and compared to placebo in a model without explanatory variables to be 1.560 (1.409, 1.734), 1.449 (0.873, 2.413) and 1.532 (1.337, 1.757) respectively. We also found all MAO-B inhibitors to be efficient when given together with levodopa. When ranking the MAO-B inhibitors given in combination with levodopa, selegiline was the most effective and rasagiline was the second best. CONCLUSIONS: All of the included MAO-B inhibitors were effective compared to placebo when given as monotherapy. Combination therapy with MAO-B inhibitors and levodopa showed that all three MAO-B inhibitors were effective compared to placebo, but selegiline was the most effective drug.
Authors: F Stocchi; G Arnold; M Onofrj; H Kwiecinski; A Szczudlik; A Thomas; U Bonuccelli; A Van Dijk; C Cattaneo; P Sala; R G Fariello Journal: Neurology Date: 2004-08-24 Impact factor: 9.910
Authors: A H V Schapira; F Stocchi; R Borgohain; M Onofrj; M Bhatt; P Lorenzana; V Lucini; R Giuliani; R Anand Journal: Eur J Neurol Date: 2012-09-12 Impact factor: 6.089
Authors: Maribel Márquez-Cruz; Juan Pablo Díaz-Martínez; Herman Soto-Molina; Adib Jorge De Saráchaga; Amin Cervantes-Arriaga; Rodrigo Llorens-Arenas; Mayela Rodríguez-Violante Journal: Expert Rev Pharmacoecon Outcomes Res Date: 2016-01-25 Impact factor: 2.217
Authors: Robert A Hauser; Fabrizio Stocchi; Olivier Rascol; Susan B Huyck; Rachel Capece; Tony W Ho; Peter Sklar; Christopher Lines; David Michelson; David Hewitt Journal: JAMA Neurol Date: 2015-12 Impact factor: 18.302